You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 9, 2025

Litigation Details for Milvio B. Gomez (Bankr. D.N.J. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Milvio B. Gomez
The small molecule drug covered by the patents cited in this case is ⤷  Try for Free .

Details for Milvio B. Gomez (Bankr. D.N.J. 2021)

Date FiledDocument No.DescriptionSnippetLink To Document
2021-08-13 766 expiration of Nippon Shinyaku’s United States Patent Nos. 7,205,302 (’302); 8,791,122 (’122); and 9,284,280 …of both asserted patents. In June 2020, the USPTO denied institution of the ’296 patent IPR and granted…granted institution of the ’603 patent IPR. UT dismissed the ’603 patent from the suit and no longer accuses… ’276 and ’906 patents. Intuitive subsequently dropped the ’200, ’473 and ’701 patents from the suit. …instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, External link to document
>Date Filed>Document No.>Description>Snippet>Link To Document
Showing 1 to 1 of 1 entries

Litigation Summary and Analysis for Milvio B. Gomez: Campbell-Ewald Co. v. Gomez

Introduction

The case of Campbell-Ewald Co. v. Gomez is a significant legal precedent that addresses the issue of whether an unaccepted settlement offer can moot a plaintiff's individual and class action claims. Here, we will summarize and analyze the key points of this litigation, focusing on the implications for class actions and the legal principles involved.

Background

Jose Gomez, the plaintiff, received unsolicited text messages from Campbell-Ewald Co., a marketing firm contracted by the U.S. Navy. Gomez alleged that these messages violated the Telephone Consumer Protection Act (TCPA), which requires prior express consent from the recipient before sending such messages[1][5].

Gomez's Claims and Class Action

Gomez filed a lawsuit on behalf of himself and a nationwide class of individuals who received similar unsolicited text messages. He sought treble statutory damages, costs, attorney’s fees, and an injunction to prevent future violations of the TCPA[1][5].

Campbell-Ewald's Settlement Offer

Before Gomez could file a motion for class certification, Campbell-Ewald Co. made an offer of judgment under Federal Rule of Civil Procedure 68. This offer included treble damages for each text message Gomez received and a stipulated injunction to prevent future violations. Additionally, Campbell-Ewald made a freestanding settlement offer with the same terms. Gomez declined both offers, allowing them to lapse after the specified 14-day period[1][5].

Mootness Argument

Campbell-Ewald argued that since they had offered Gomez complete relief, his individual claim was moot. They further argued that because Gomez’s individual claim was moot before he could move for class certification, the putative class action was also moot. Campbell-Ewald moved to dismiss the case for lack of subject matter jurisdiction under Federal Rule of Civil Procedure 12(b)(1)[1][5].

District and Appellate Court Rulings

The district court denied Campbell-Ewald's motion to dismiss, holding that the unaccepted settlement offers did not moot Gomez’s individual or class claims. On appeal, the Ninth Circuit Court of Appeals also rejected Campbell-Ewald's argument, affirming the district court's decision[1][5].

Supreme Court Decision

The Supreme Court affirmed the Ninth Circuit's decision. Justice Ginsburg, writing for the majority, held that an unaccepted settlement offer or offer of judgment does not moot a plaintiff’s case. The Court adopted Justice Kagan’s dissent from Genesis Healthcare v. Symczyk, which stated that an unaccepted settlement offer is a "legal nullity, with no operative effect"[1][5].

Key Legal Principles

  • Mootness Doctrine: The Supreme Court clarified that an unaccepted settlement offer does not render a plaintiff's claim moot. This decision prevents defendants from using settlement offers as a strategy to avoid class actions by mooting the named plaintiff's claim before class certification can be sought.
  • Contract Law: The Court emphasized that an unaccepted offer, like any unaccepted contract offer, has no legal effect and does not change the parties' stakes in the litigation.
  • Class Actions: The decision ensures that class actions can proceed even if the defendant offers complete relief to the named plaintiff but does not address the claims of the putative class members[1][5].

Implications

The Campbell-Ewald decision has significant implications for class action litigation:

  • Protection of Class Actions: It prevents defendants from using settlement offers as a tactic to moot class actions, thereby protecting the rights of class members to seek collective relief.
  • Encouraging Litigation: By ensuring that class actions can proceed despite offers of complete relief to the named plaintiff, the decision encourages plaintiffs to pursue class actions to address widespread violations of law.
  • Legal Certainty: The ruling provides clarity on the effect of unaccepted settlement offers, reducing the likelihood of defendants attempting to use such offers to dismiss class actions prematurely[1][5].

Conclusion

The Campbell-Ewald Co. v. Gomez case is a landmark decision that reinforces the integrity of class action litigation. It underscores the principle that an unaccepted settlement offer does not moot a plaintiff's claim, thereby safeguarding the ability of class members to seek justice collectively.

Key Takeaways

  • An unaccepted settlement offer or offer of judgment does not moot a plaintiff’s individual or class claims.
  • Class actions can proceed even if the defendant offers complete relief to the named plaintiff but does not address the claims of the putative class members.
  • The decision prevents defendants from using settlement offers as a strategy to avoid class actions.
  • The ruling provides legal certainty and encourages the pursuit of class actions to address widespread legal violations.

Frequently Asked Questions (FAQs)

Q: What was the central issue in the Campbell-Ewald Co. v. Gomez case? A: The central issue was whether an unaccepted settlement offer or offer of judgment could moot a plaintiff's individual and class action claims.

Q: What was the outcome of the Supreme Court's decision in this case? A: The Supreme Court held that an unaccepted settlement offer or offer of judgment does not moot a plaintiff’s case.

Q: How does this decision impact class action litigation? A: It prevents defendants from using settlement offers to dismiss class actions prematurely and ensures that class actions can proceed to address the claims of all class members.

Q: What legal principle did the Supreme Court rely on in its decision? A: The Court relied on the principle that an unaccepted offer is a "legal nullity, with no operative effect," as stated in Justice Kagan’s dissent from Genesis Healthcare v. Symczyk.

Q: What are the implications of this decision for defendants in class action cases? A: The decision discourages defendants from using settlement offers as a tactic to avoid class actions, ensuring that class members can seek collective relief.

Cited Sources

  1. Harvard Law Review: Campbell-Ewald Co. v. Gomez.
  2. Supreme Court of the United States: Campbell-Ewald Co. v. Gomez, 577 U.S. 14-857.
  3. Justia: Campbell-Ewald Co. v. Gomez, 577 U.S. 14-857.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.